Terns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $7.50

Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) had its price objective increased by stock analysts at HC Wainwright from $5.50 to $7.50 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. HC Wainwright’s price target points to a potential upside of 9.17% from the stock’s […]

Leave a Reply

Your email address will not be published.

Previous post Camtek (NASDAQ:CAMT) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
Next post Merck & Co., Inc. (NYSE:MRK) Shares Sold by D Orazio & Associates Inc.